PROCEPT BioRobotics (PRCT) Q2 2026 earnings review
Record Pricing Masks Severe Cracks in Procedure Volume
PROCEPT delivered a seemingly stable quarter with 19% YoY revenue growth and gross margins expanding to 66%, anchored by exceptional pricing discipline. However, beneath the surface, the core growth narrative has fractured. Management drastically cut full-year U.S. procedure guidance to 54,000-56,000 (from 60,000-64,000) and widened the Adjusted EBITDA loss forecast, abruptly abandoning their timeline for Q4 profitability. The commercial realignment is evidently causing deeper and more prolonged disruption than the 'short-term' blip pitched last quarter. Pricing power is currently the sole buoy keeping the revenue guidance afloat.
🐂 Bull Case
The strategy to eliminate discounts is working flawlessly. U.S. handpiece ASPs hit ~$3,550 (+11% YoY), beating the FY26 target of $3,500. HYDROS system ASPs climbed further to ~$495,000.
The company placed 14 replacement HYDROS systems this quarter, a massive acceleration from just 2 in Q1. This creates a highly profitable secondary capital revenue stream.
🐻 Bear Case
The cut to full-year procedure volume by roughly 6,000 units is a severe red flag. YoY growth decelerated to 21% in Q2, calling into question the effectiveness of the new dedicated launch teams.
Widening the FY26 Adjusted EBITDA loss guidance to $30M-$35M contradicts previous explicit promises of reaching profitability by Q4 2026, indicating operating leverage has stalled.
⚖️ Verdict: 🔴
Bearish. While extracting maximum price from hospitals is an excellent near-term lever, medical device valuations depend on utilization. Slashing procedure guidance and pushing out profitability points to execution failures in the commercial realignment.
Key Themes
Procedure Guidance Slashed, Revealing Deep Commercial Disruption
Decelerating. In Q1, management heavily defended a 60,000-64,000 FY26 procedure target (39-48% growth). Just one quarter later, they slashed it to 54,000-56,000 (25-29% growth). Q2 U.S. procedures came in at 13,100 (+21% YoY), marking a steep deceleration from Q1's +30% and Q4's +69%. This heavily implies that the recent commercial realignment and transition to dedicated launch teams is causing structural disruption, rather than just the transient friction management originally claimed.
Profitability Trajectory Reverses
Reversing. PROCEPT previously modeled Q4 2026 as its crossover point to Adjusted EBITDA profitability, guiding for an FY26 loss of $17M-$30M. They have now widened that loss expectation to $30M-$35M. Total operating expenses surged to $89.8M in Q2 (up 21% YoY). Higher pricing is not flowing to the bottom line, offset by heavy investments in the commercial organization and the WATER IV trial. The path to profitability is now materially delayed.
Ironclad Pricing Discipline
Accelerating. The controversial Q4 2025 decision to end quarter-end bulk discounts is paying massive dividends. U.S. handpiece ASPs reached ~$3,550 (+11% YoY), already beating management's full-year target of $3,500. Simultaneously, U.S. HYDROS system ASPs increased to ~$495,000, up from ~$485,000 in Q1. This pricing power is the singular reason PROCEPT could reiterate FY26 revenue guidance despite a massive cut to procedure volumes.
Replacement Capital Cycle Ignites
Accelerating. Out of 65 U.S. HYDROS placements this quarter, 14 were replacements of older systems. This is a dramatic acceleration from Q1, where only 2 of 49 systems were replacements. This signals that the 5-7 year replacement cycle for early Aquabeam systems is beginning in earnest, establishing a high-margin secondary revenue stream that requires less 'greenfield' market education.
Tariff Relief Bolsters Margins
Macro environment tailwind. Gross margin expanded to 66% (up from 65% in Q1 2026 and Q2 2025), aided significantly by a $2.9 million tariff refund. This refund temporarily offsets the structural COGS pressure the company has faced from Chinese supply chain tariffs, buying time as they navigate margin expansion via ASP increases.
WATER IV Trial Completion & Strengthened AUA Guidelines
Stable. The company achieved two major clinical and technological milestones. First, the American Urological Association (AUA) updated its guidelines to include a 'strengthened recommendation' for Aquablation. Second, enrollment for the WATER IV prostate cancer study is officially complete. Both developments fortify the competitive moat of the HYDROS AI-powered platform and support long-term adoption, even if near-term commercial execution is stumbling.
Handpiece to Procedure Ratio Still Strained
Stable. U.S. handpieces sold as a percent of U.S. procedures was ~98% in Q2, up slightly from 95% in Q1 but still below the stated target of a 1:1 ratio. While improving, this indicates there may still be residual inventory bleed occurring in the channel, validating earlier analyst fears about channel stuffing under previous sales regimes.
Other KPIs
Accelerating. OpEx grew 21% YoY from $73.9M in Q2 2025 and stepped up sequentially from $86.5M in Q1 2026. Management attributes this to commercial organization investments and WATER IV clinical trial costs, but the resulting negative leverage directly triggered the cut to EBITDA guidance.
Decelerating. Grew 15% YoY, representing a sharp drop-off from the 69% YoY growth seen in Q2 2025 and 25% YoY growth in Q1 2026. While international remains a focus, domestic execution is clearly demanding the majority of corporate bandwidth.
Guidance
Stable. The company reiterated its full-year guidance range, representing 27% to 33% YoY growth. Achieving this while cutting procedure volume heavily relies on maintaining or increasing current record ASP levels.
Decelerating sharply. Slashed from the prior guidance of 60,000-64,000. This implies 25% to 29% YoY growth, a stark breakdown from the 39% to 48% growth management pitched just three months prior. This is the quarter's most concerning metric.
Reversing. Downward revision from prior expectations of a $17M-$30M loss. This widening loss negates previous promises of achieving Adjusted EBITDA profitability by Q4 2026, driven by an inability to leverage operating expenses against falling procedure volumes.
Stable. Reiterated for the full year. Q2's 66% performance was aided by a $2.9M tariff refund, implying underlying organic margins for the second half will likely normalize closer to the 65% baseline.
Key Questions
Root Cause of Procedure Disruption
You cut full-year procedure guidance by roughly 6,000 units after heavily defending it last quarter. How much of this shortfall is directly attributable to temporary disruption from the sales force realignment versus a fundamental stalling in physician adoption?
Profitability Timeline
With Adjusted EBITDA loss guidance widening to $30M-$35M, the path to Q4 profitability appears broken. What is the new anticipated quarter for achieving Adjusted EBITDA breakeven, and what structural changes are required to get there?
Replacement Cycle Trajectory
HYDROS replacements jumped to 14 units this quarter. As the early 2020-2021 Aquabeam cohort ages out, what percentage of your total capital placement mix do you expect replacements to comprise by year-end?
Revenue vs Procedure Divergence
You reiterated revenue guidance despite a massive cut to procedures, implying pricing will bridge the gap. Given hospital capital scrutiny, how sustainable is a ~$495,000 system ASP if utilization ramps are materially slower than projected?